Therapeutic Asset Ratings
142 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
bi 765883
Pancreatic Ductal Adenocarcinoma
Boehringer Ingelheim
P1
C
(37)
CARMUSTINE
Pancreatic Ductal Adenocarcinoma
General Oncology, Inc.
P1
C
(37)
Dcc-3084
Pancreatic Ductal Adenocarcinoma
Deciphera Pharmaceuticals, LLC
P1
C
(37)
dr-0202
Pancreatic Ductal Adenocarcinoma
Dren Bio
P1
C
(37)
Drug: Ibi3028
Pancreatic Ductal Adenocarcinoma
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
P1
C
(37)
Evomela
Pancreatic Ductal Adenocarcinoma
General Oncology, Inc.
P1
C
(37)
Ezabenlimab
Pancreatic Ductal Adenocarcinoma
Boehringer Ingelheim
P1
C
(37)
Falimarev
Pancreatic Ductal Adenocarcinoma
National Cancer Institute (NCI)
P1
C
(37)
FLUTICASONE
Pancreatic Ductal Adenocarcinoma
National Cancer Institute (NCI)
P1
C
(37)
Fpi-2053
Pancreatic Ductal Adenocarcinoma
AstraZeneca
P1
C
(37)
Futibatinib
Pancreatic Ductal Adenocarcinoma
Taiho Pharmaceutical Co., Ltd.
P1
C
(37)
[Ga-68]-PNT6555
Pancreatic Ductal Adenocarcinoma
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
P1
C
(37)
hu5B1-TCO
Pancreatic Ductal Adenocarcinoma
Memorial Sloan Kettering Cancer Center
P1
C
(37)
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER
Pancreatic Ductal Adenocarcinoma
Taiho Pharmaceutical Co., Ltd.
P1
C
(37)
immunoglobulin G1-kappa, anti-[Homo sapiens TIGIT (T-cell immunoreceptor with Ig domain and ITIM, V-set Ig member 9, VSIG9, V-set and transmembrane member 3, VSTM3)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV3-48*01 (90.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1-119) -Homo sapiens IGHG1*01, G1m17,1, G1v14 CH2 A1.3, A1.2 (CH1 K120 (216) (120-217), hinge 1-15 (218-232), CH2 L1.3>A (236), L1.2>A (237) (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-16*01 (89.5%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228'':231-231'')-bisdisulfide, produced in a Chinese hamster ovary (CHO)-K1 cell line, glycoform alfa
Pancreatic Ductal Adenocarcinoma
Taiho Pharmaceutical Co., Ltd.
P1
C
(37)
Inalimarev
Pancreatic Ductal Adenocarcinoma
National Cancer Institute (NCI)
P1
C
(37)
Itraconazole
Pancreatic Ductal Adenocarcinoma
AbbVie
P1
C
(37)
Janx008
Pancreatic Ductal Adenocarcinoma
Janux Therapeutics
P1
C
(37)
[Lu-177]-Pnt6555
Pancreatic Ductal Adenocarcinoma
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
P1
C
(37)
ly3962673
Pancreatic Ductal Adenocarcinoma
Eli Lilly and Company
P1
C
(37)
ly4066434.
Pancreatic Ductal Adenocarcinoma
Eli Lilly and Company
P1
C
(37)
NT-112
Pancreatic Ductal Adenocarcinoma
AstraZeneca
P1
C
(37)
PANITUMUMAB
Pancreatic Ductal Adenocarcinoma
Astellas Pharma Inc
P1
C
(37)
pf-08046050
Pancreatic Ductal Adenocarcinoma
Seagen, a wholly owned subsidiary of Pfizer
P1
C
(37)
pf-08046052
Pancreatic Ductal Adenocarcinoma
Seagen, a wholly owned subsidiary of Pfizer
P1
C
(37)
Showing 101 to 125 of 142 assets
Previous
Page 5 of 6
Next
